Conclusion: This study will assist with future work on identifying gaps, deficiencies and areas of need in populations with a high incidence of a key oncogenic mutation.
small-cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors (TKIs) treatment. However, the incidence of HBV reactivation in patients treated with EGFR TKI has not yet been reported.
Methods:
We enrolled 143 patients who were diagnosed as NSCLC from 2011 through 2015 and had positive hepatitis B surface antigen (HBsAg). All patients had received EGFR-TKIs as anti-cancer treatment during there treatment courses. Reactivation of HBV is defined as one of following: increase in HBV DNA by at least a 10-fold compared to baseline, absolute increase to> 10^8IU/mL or HBV viral load>2000 IU/mL and ALT level > 5 times the upper limit of normal. Background and Aims: Adenosquamous cell carcinoma (ADSQCC) of the lung is a rare subtype of non-small cell carcinoma that is composed of at least 10% by volume each of squamous cell carcinoma and adenocarcinoma cells. There is few literature addressing the frequency of epidermal growth factor receptor (EGFR) and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangement in this subset of lung carcinomas. We analyzed the detection rate of somatic gene mutations in ADSQCC of lung, focusing the EGFR mutation and EML4-ALK rearrangement.
We retrospectively analyzed patients with adenosquamous cell carcinoma of the lung who underwent surgical resection or biopsy between January 2012 and December 2017. EGFR mutations and EML4-ALK rearrangement were assessed in all of the patients. Detection of the EGFR mutation status was performed by direct sequencing or a commercial real-time PCR kit and EML4-ALK rearrangement was performed by fluorescence in situ hybridization (FISH).
Results: A total of 16 patients were selected in study period. The patients included 14 men and 2 women, mean age 75.9 years (range 61-86 years). In 8 cases (50%) underwent surgical resection and the others (8 cases) underwent percutaneous needle biopsy.
Overall, 3 (18.8%) of 16 patients had EGFR mutations: two patients had an exon 19 deletion and one had an exon 21, L858R mutation. There were no T790 M mutations. Only one cases (6%), there were EML4-ALK rearrangement.
Conclusion: EGFR mutations occur in lung ADSQCC in the lower percentages as in conventional adenocarcinoma in the Asian population.
EML4-ALK rearrangement is less common. 
